We analyzed the association between the expression of CD22 and clinicopathological features (age, depth of tumor invasion, lymph node metastasis, histologic grade, clinical stage, and Ki67 expression) of 97 TNBC patients (Table 3, p < 0.05). This evidence concerns the gene CD22 and metastatic malignant neoplasm in the lymph nodes.